UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 8-K

CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported): **March 17, 2026**

Pulse Biosciences, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Delaware	**001-37744**	**46-5696597**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

601 Brickell Key Drive, Suite 1080
Miami, Florida 33131
(Address of Principal Executive Offices) (Zip Code)

510-906-4600
(Registrant's Telephone Number, Including Area Code)

Not Applicable
(Former Name or Former Address, If Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class	Trading Symbol(s)	Name of Each Exchange on Which Registered
Common stock, $0.001 par value per share	PLSE	The Nasdaq Stock Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 8.01 Other Events.

On March 17, 2026, Pulse Biosciences, Inc. (the "Company") issued a press release announcing an organizational realignment to support the Company's increasing focus on developing its nsPFA electrophysiology catheters and other cardiac devices for the treatment of atrial fibrillation ("AFib"). This decision follows the Company's release of unprecedented clinical data, on February 5, 2026, from its first in human feasibility study of its proprietary nPulse Cardiac Catheter System in patients with paroxysmal AFib. In the short-term, this announced realignment will result in a reduction in the number of employees in the Company's sales and marketing functions, while it continues to actively recruit into its other product development functions.

A copy of the press release related to the matters set forth herein is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	**Description**
99.1	Press Release issued by Pulse Biosciences, Inc. dated March 17, 2026 - Pulse Biosciences, Inc. Announces Realignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

PULSE BIOSCIENCES, INC.

Date: March 17, 2026

By: /s/ Jon Skinner
Jon Skinner
Chief Financial Officer
(Principal Financial Officer)

Exhibit 99.1

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

HAYWARD, California [Business Wire] — March 17, 2026. Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System.

"The European feasibility data from over 150 patients sends a definitive message," said Bob Duggan, Co-Chairman of Pulse Biosciences. "The nPulse clinical performance demonstrates a clear potential to change clinical practice for the health treatment of millions of patients. Our mission to support this program deserves our highest priority, and we are updating our capital allocation to align with this extraordinary opportunity."

Paul LaViolette, CEO and Co-Chairman, added: "We are thrilled to be allocating additional resources to the vast potential of our catheter-based EP program. We are fortifying a program that has already shown the potential to be first-in-class and best-in-class."

This initiative follows the announcement of groundbreaking clinical outcomes from the Company's 150-patient European feasibility study, which demonstrated that nsPFA delivers a unique combination of speed, safety, and long-term durable efficacy in treating Atrial Fibrillation (AFib).

The Data: Unprecedented Clinical Outcomes

The decision to centralize resources on the Cardiac Catheter program is backed by data recently presented at the 31st Annual AF Symposium, which positions nPulse as a best-in-class solution:

- **100% Procedural Success at 6 Months:** 75/75 evaluable patients achieved acute Pulmonary Vein Isolation (PVI) success.
- **96% Sustained Success at 12 Months:** Long-term follow-up (45/47 patients) confirmed highly durable Pulmonary Vein Isolation (PVI), exceeding traditional expectations in a field where approximately 20-25% recurrence is common.
- **Industry-Leading Procedural Efficiency:**
    - **Left Atrial Dwell Time: 21.0 ± 13.3 minutes**, this would reduce the time spent inside the heart.
    - **Total Procedure Time:** Averaged **65 minutes**, including only 9.8 minutes of fluoroscopy.
    - **Ease of Use:** Success was achieved with an average of **16.1 applications** per procedure.
- **Safety Profile:** A low 1.3% rate of Serious Adverse Events (SAEs) related to the primary safety endpoint.

Strategic Resource Alignment: Focus on High-Value Growth

To capitalize on these groundbreaking results, Pulse Biosciences is modifying its capital allocation to prioritize the Electrophysiology (EP) market development program:

- **Primary Focus:** The majority of R&D and clinical investment is now dedicated to the nPulse Cardiac Catheter program's upcoming pivotal IDE study in the United States and Europe and corresponding regulatory submission.
- **Surgical Program Calibration:** While the Company remains committed to the Surgical Clamp IDE enrollment, it will reduce short term market development investments in cardiac surgery.
- **Soft-Tissue Ablation Optimization:** Operations for the percutaneous soft-tissue ablation system have been streamlined to reduce spend on sales and marketing and focusing on market development by progressing the Vybrance Percutaneous Electrode System towards an on-label indication for the treatment of benign thyroid nodules, driving real-world utilization data, and validating reimbursement rates, thereby allowing for a reduction in investment that can be redirected to the catheter program.

Upcoming Milestones

Late breaking clinical data on the treatment of AFib using the nPulse Cardiac Catheter System has been accepted for presentation at Heart Rhythm 2026, in Chicago, IL. A late-breaking data presentation by Vivek Reddy, MD, Director of Cardiac Arrhythmia Services at the Mount Sinai Fuster Heart Hospital, NY, will include additional 12-month follow-up data from the nPulse Cardiac Catheter first-in-human feasibility study. The presentation is scheduled for April 25 from 11:45–11:55 a.m. CT.

About Pulse Biosciences®

Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the intention as well as potential to improve the quality of life for patients. The Company's proprietary nPulse™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its nPulse technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers, such as surgical soft tissue ablation.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements, including, among other things, statements concerning early clinical successes and whether they are predictive of the safety and effectiveness of any medical device such as the nPulse Cardiac Catheter, Pulse Biosciences' expectations, whether stated or implied, about whether the Company's nsPFA technology will become either a disruptive treatment option or a superior option for treating atrial fibrillation or any other medical condition, statements relating to the effectiveness of the Company's nsPFA technology and nPulse System to non-thermally clear cells while sparing adjacent non-cellular tissue, statements concerning the Company's expected product development efforts, such as advancement of its nPulse Cardiac Catheter to treat paroxysmal atrial fibrillation, statements concerning whether the anticipated reduction in expenditures in the Company's cardiac surgery and surgical ablation programs will enable the Company to accelerate product development activities in its electrophysiology program, and other future events. These statements are not historical facts but rather are based on Pulse Biosciences' current expectations, estimates, and projections regarding Pulse Biosciences' business, operations and other similar or related factors. Words

such as “may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,” “potential,” “continue,” “expects,” “intends,” “plans,” “projects,” “believes,” “estimates,” and other similar or related expressions are used to identify these forward-looking statements, although not all forward-looking statements contain these words. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and assumptions that are difficult or impossible to predict and, in some cases, beyond Pulse Biosciences’ control. Actual results may differ materially from those in the forward-looking statements as a result of a number of factors, including those described in Pulse Biosciences’ filings with the Securities and Exchange Commission. Pulse Biosciences undertakes no obligation to revise or update information in this release to reflect events or circumstances in the future, even if new information becomes available.

Investor Contact:
Pulse Biosciences, Inc.
Jon Skinner, CFO
IR@pulsebiosciences.com

Or

Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com